e0067 Aspirin attenuates pulmonary arterial hypertension in rats by reducing plasma 5hydroxytryptamine level
作者： S. Lan , S. Jieyan , B. Jun , Y. Ancai
DOI: 10.1136/HRT.2010.208967.67
关键词: Internal medicine 、 Survival rate 、 Platelet aggregation inhibitor 、 Gastroenterology 、 Anesthesia 、 Aspirin 、 Thrombosis 、 Platelet 、 Dose 、 Pulmonary hypertension 、 Medicine 、 Pathological
摘要: Pulmonary arterial hypertension (PAH) is characterised by increasing pulmonary pressure, right ventricular failure, and death. The typical pathological changes include medial hypertrophy, intimal fibrosis in situ thrombosis. 5-HT other factors contributed to the development of pathologic lesions. Aspirin (ASA), platelet aggregation inhibitor, inhibits release from platelet. aim current study was determine efficacy aspirin preventing or attenuating hypertension. Sprague-Dawley (SD) rats injected with monocrotaline (MCT) at day 0 developed severe PAH 31. Rats were randomised receive either vehicle different dosages (ASA 0.5 mg/kg/d, ASA 1 mg/kg/d, 2 mg/kg/d, 4 mg/kg/d). suppressed increased survival rate compared placebo group (84% vs 60%, p
springer.com
sci-hub.se 参考文章(25)
Gurtner Hp, Aminorex and pulmonary hypertension. A review. Cor et vasa. ,vol. 27, pp. 160- 171 ,(1985)
F. De Clerck, The role of serotonin in thrombogenesis. Clinical physiology and biochemistry. ,vol. 8, pp. 40- 49 ,(1990)
Jieyan Shen, Ben He, Binyao Wang, None, Effects of lipo-prostaglandin E1 on pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension. Chest. ,vol. 128, pp. 714- 719 ,(2005) , 10.1016/S0012-3692(15)50417-0
M. R. MacLean, Pulmonary hypertension and the serotonin hypothesis: where are we now? International Journal of Clinical Practice. ,vol. 61, pp. 27- 31 ,(2007) , 10.1111/J.1742-1241.2007.01497.X
Marion Delcroix, Christian Melot, Philippe Lejeune, Marc Leeman, Robert Naeije, Cyclooxygenase Inhibition Aggravates Pulmonary Hypertension and Deteriorates Gas Exchange in Canine Pulmonary Embolism American Review of Respiratory Disease. ,vol. 145, pp. 806- 810 ,(1992) , 10.1164/AJRCCM/145.4_PT_1.806
Carl Carlino, Rebecca I. Schneider, Kevin C. Dellsperger, Joseph D. Tobias, Randall L. Heller, Vincent G. Demarco, Ryan E. Grueber, Martin A. Alpert, Pulmonary hemodynamic response to acute combination and monotherapy with sildenafil and brain natriuretic peptide in rats with monocrotaline-induced pulmonary hypertension. The American Journal of the Medical Sciences. ,vol. 339, pp. 55- 59 ,(2010) , 10.1097/MAJ.0B013E3181C078D7
Philipe Hervé, Jean-Marie Launay, Marie-Laurène Scrobohaci, François Brenot, Gérald Simonneau, Patrick Petitpretz, Patrice Poubeau, Jacques Cerrina, Pierre Duroux, Ludovic Drouet, Increased plasma serotonin in primary pulmonary hypertension. The American Journal of Medicine. ,vol. 99, pp. 249- 254 ,(1995) , 10.1016/S0002-9343(99)80156-9
E Hironaka, Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats Cardiovascular Research. ,vol. 60, pp. 692- 699 ,(2003) , 10.1016/J.CARDIORES.2003.09.023
A. E. Schultze, R. A. Roth, Chronic pulmonary hypertension--the monocrotaline model and involvement of the hemostatic system. Journal of Toxicology and Environmental Health-part B-critical Reviews. ,vol. 1, pp. 271- 346 ,(1998) , 10.1080/10937409809524557
Dušan Kentera, Dinko Sušić, Mirjana Zdravković, Effects of verapamil and aspirin on experimental chronic hypoxic pulmonary hypertension and right ventricular hypertrophy in rats. Respiration. ,vol. 37, pp. 192- 196 ,(1979) , 10.1159/000194026